Rhumbline Advisers Xtl Biopharmaceuticals LTD Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Xtl Biopharmaceuticals LTD stock. As of the latest transaction made, Rhumbline Advisers holds 17,261 shares of XTLB stock, worth $23,820. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,261
Previous 10,954
57.58%
Holding current value
$23,820
Previous $13,000
46.15%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding XTLB
# of Institutions
6Shares Held
430KCall Options Held
0Put Options Held
0-
Noked Capital LTD Tel Aviv, L3199KShares$274,4650.02% of portfolio
-
Noked Israel LTD Ramat Hasharon, L3199KShares$274,4650.04% of portfolio
-
Morgan Stanley New York, NY13.3KShares$18,2860.0% of portfolio
-
Ubs Group Ag1.34KShares$1,8430.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$0100.0% of portfolio
About XTL BIOPHARMACEUTICALS LTD
- Ticker XTLB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,449,060
- Market Cap $7.52M
- Description
- XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...